

TABLE 1 Clinical characteristics of four rhabdoid tumor cases

Case	Year at diagnosis	Family history	Primary site & size (cm)	Blood examination	Metastasis	Chemotherapy	Surgery	Local radiation	SMARCB1 status	Outcome (from Dx)	Late complication
1	1991	None	left kidney 8.2 × 8.2 × 5.8	LDH 685 IU/L	lymph nodes	ActD+VCR (3m)→	total resection	Cobalt	partial deletion of exon 6	DOD (11 m)	-
						ActD+VCR+DOX (2m)→					
						AST 106 IU/L					
						VDC+VP+CDDP→					
2	2000	leukemia (paternal grandfather) parathyroid gland cancer (maternal grandmother)	chest wall 6.5 × 4.5 × 2.5	LDH 493 IU/L	no	IFO+THP→	total resection	30.6 Gy	homozygous deletion	NED (15 y)	asymmetrical thorax
						MMC+VCR+THP					
						VDC+IE (4cycles)→					
						relapse→					
3	2003	None	left kidney 10.0 × 8.5 × 8.0	Ca 14.1 mg/dL LDH 2886 IU/L	no	VCR or VP+THP+CPM+CDDP (3cycles)	total resection	not done	C157T Copy number LOH	DOD (9 m)	-
						CBDCA+VP (2cycles)→					
						ICE→					
						VCR+THP+CPM (3cycles)→					
4	2007	gastric cancer (father)	retro- peritoneum 4.0 × 3.5 x 4.0	None	no	IE→	residual tumor around ureter	41.4 Gy	whole homozygous deletion	NED (11 y)	pelvic deformation, constipation, pollakiuria, short stature
						VCR+ActD+IFO					
						→CPT-11					
						VDC+ICE (5cycles)					

Abbreviations: ActD, dactinomycin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Ca, calcium; CBDCA, carboplatin; CDDP, cisplatin; CPM, cyclophosphamide; CPT-11, irinotecan; DOD, dead of disease; DOX, doxorubicin; Dx, diagnosis; ICE, ifosfamide + carboplatin + etoposide; IE, ifosfamide + etoposide; IFO, ifosfamide; LDH, lactate dehydrogenase; LOH, loss of heterozygosity; MMC, mitomycin C; NED, no evidence of disease; THP, tetrahydropyranyl-doxorubicin; VCR, vincristine; VDC, vincristine + doxorubicin + cyclophosphamide; VP, etoposide.